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Formate overﬂow coupled to mitochondrial oxidative metabolism\ has been observed in
cancer cell lines, but whether that takes place in the tumor microenvironment is not known.
Here we report the observation of serine catabolism to formate in normal murine tissues,
with a relative rate correlating with serine levels and the tissue oxidative state. Yet, serine
catabolism to formate is increased in the transformed tissue of in vivo models of intestinal
adenomas and mammary carcinomas. The increased serine catabolism to formate is asso-
ciated with increased serum formate levels. Finally, we show that inhibition of formate
production by genetic interference reduces cancer cell invasion and this phenotype can be
rescued by exogenous formate. We conclude that increased formate overﬂow is a hallmark of
oxidative cancers and that high formate levels promote invasion via a yet unknown
mechanism.
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In his 1956 landmark paper Otto Warburg hypothesized thatcancer is caused by mitochondrial defects that result inincreased rates of glycolysis with lactate overﬂow1. Today
increased glycolysis is an established hallmark of cancer meta-
bolism and forms the scientiﬁc basis for Positron Emission
Tomography (PET) scans. In contrast, the Warburg hypothesis
that cancers harbor defective mitochondria has remained con-
troversial2. Recent evidence indicates that some tumors have
rates of glucose oxidation comparable to those observed in nor-
mal tissues3, 4, challenging the assumption that cancer cells are
characterized by defective mitochondrial metabolism.
A pathway that relies on functional mitochondria is the oxi-
dation of the third carbon of serine to formate5. Formate pro-
duced in the mitochondria is released into the cytosol where
it supplies the one-carbon demand for nucleotide synthesis6
(Fig. 1). Formate can also be recycled back to re-synthesize serine
via cytosolic one-carbon metabolism7. In cells with defective
mitochondrial one-carbon metabolism, the cytosolic pathway is
reverted compensating for the loss of mitochondrial formate
production7. When both cytosolic and mitochondrial pathways
are compromised cells can utilize exogenous formate7 or endo-
genous formaldehyde8 as alternative sources of one-carbon units.
We predicted9 and experimentally veriﬁed10 that serine cata-
bolism, and subsequent formate production, often occurs at rates
exceeding the one-carbon demand of biosynthesis. The excess
formate is then released from the cells, a process referred to
as formate overﬂow. Formate overﬂow is dependent on the
expression of mitochondrial one-carbon metabolism enzymes
and competent oxidative phosphorylation10, 11. In vitro cell cul-
tures treated with complex I inhibitors10 or harboring mito-
chondrial DNA mutations11 manifest reduced formate release or
even switch to formate uptake. Treatment of mice with the
complex I inhibitor phenformin inhibits the whole body rate of
serine catabolism to plasma formate10. However, whether formate
overﬂow is observed in tumors in vivo and if it is dependent on
oxidative metabolism remains to be elucidated.
Here we develop experimental methods to investigate the
link between formate overﬂow and redox state in vivo, and
to measure the rate of serine catabolism to formate in tissues.
Using these methods, we uncover a basal serine catabolism
to formate in normal tissues, with tissue speciﬁc rates in
increasing order of their serine levels and oxidative proﬁle. To
estimate the rate of serine catabolism in cancer tissue, we ana-
lyzed intestinal adenomas from APCMin/+ mice and mammary
carcinomas of PyMT mice. Both, the intestinal adenomas and the
mammary carcinomas, exhibit signiﬁcantly increased rates of
serine catabolism to formate compared to normal adjacent
tissue and other non-tumor-bearing organs. In addition, plasma
formate levels were signiﬁcantly increased in tumor bearing mice
compared to wild-type mice in different genetically engineered
mouse models (GEMMs) of cancer compared to control mice.
This indicates that the tumor-speciﬁc high serine catabolism is
causative for the elevated plasma formate levels. Finally, we show
that inhibition of formate production by genetic knockdown
reduces invasion and that this phenotype can be rescued by
exogenous formate. We conclude that some cancers are char-
acterized by signiﬁcant oxidative metabolism, we identify formate
overﬂow as the hallmark of such oxidative cancer types and we
propose cell invasion as a possible selective advantage of formate
overﬂow.
Results
Formate overﬂow is controlled by the redox state in vitro. In
vitro studies indicate that formate release requires active mito-
chondrial oxidative phosphorylation5, 10, 11. However, measuring
oxidative phosphorylation in vivo is challenging. Since oxidative
phosphorylation is a major pathway to oxidize NADH, we rea-
soned that the NAD+/NADH redox ratio could be used to
investigate the link between the oxidation state and formate
release (Fig. 1a). Based on this evidence we formulated the
hypothesis that formate release can be used as readout for
the whole cell NAD+/NADH ratio.
To test this hypothesis we analyzed a panel of different cancer
cell lines that are routinely used in our laboratory to investigate
one-carbon metabolism (Supplementary Table 1). We quantiﬁed
extracellular formate concentration using a benzyl alcohol
derivatization protocol followed by GC-MS12 and calculated
exchange rates of formate release. We also quantiﬁed intracellular
NAD+ and NADH using LC-MS and calculated the NAD
+/NADH ratio. Plotting the rate of formate release as a function
of the NAD+/NADH ratio uncovered a linear relationship
between these two variables across cancer cell lines (Fig. 1b,
Pearson Correlation Coefﬁcient PCC= 0.89, p-value= 0.001,
excluding the outlier (triangle down)).
To address the validity of our observations in a homogenous
genetic background, we analyzed HAP1 cells under different
environmental and pharmacological perturbations that alter the
cell redox state, albeit by different mechanisms. Here we also
introduce the serine catabolism index SCI= Serine × NAD
+/NADH, which takes into account that the serine catabolism
rate is determined by both the redox state and the serine
concentration10. First, we investigated the impact of switching
cells from glucose to galactose containing medium, which results
in growth inhibition and increases oxidative phosphorylation10.
When HAP1 cells where cultured in galactose serine levels did
not change signiﬁcantly relative to cells in glucose (Fig. 1c, p=
0.33, unpaired t-test). In contrast, the NAD+/NADH ratio and
consequently SCI increased with a statistical signiﬁcance close
to 0.05 (Fig. 1d (p= 0.06), Fig. 1e (p= 0.08), unpaired t-test). In
agreement with the SCI increase, formate release also increased
with a statistical signiﬁcance close to 0.05 (Fig. 1f, p= 0.06,
unpaired t-test).
Next, we treated cells with 50 nM of the antifolate methotrexate
(MTX), a well-known inhibitor of purine synthesis, thymidylate
synthesis and growth (Supplementary Fig. 1). MTX treatment
depletes intracellular thymidylate and ATP and suppresses cell
proliferation (Supplementary Fig. 1c, e, f), thereby decreasing
the rate of NADH generation. Serine levels did not change
signiﬁcantly upon MTX treatment (Fig. 1g, p= 0.44, unpaired
t-test). In contrast, NAD+/NADH and consequently SCI
increased (Fig. 1h (p= 0.01), Fig. 1e (p= 0.02) unpaired t-test).
The MTX treated cells had a modest increase in oxygen
consumption (Supplementary Fig. S1b), indicating that the shift
towards more oxidized NAD+ might be a combined effect of
increase in oxidative phosphorylation and decrease in growth.
More importantly, the MTX dependent shift to a more oxidative
state is associated with a signiﬁcant increase of formate release
(Fig. 1j, p= 0.003, unpaired t-test). This observation was
surprising given that MTX is an antifolate and one-carbon
metabolism is folate dependent. Yet, using [U-13C]-Serine tracing
we corroborated that there was an increase in 13C-formate
release from cells (Supplementary Fig. 1d). Therefore, at a 50 nM
dose, MTX does not inhibit the serine catabolism to formate
while growth and one-carbon metabolism dependent nucleotide
synthesis is inhibited.
Finally, we tested our hypothesis in the context of hypoxia,
where oxygen dependent oxidation processes are inhibited to the
degree the oxygen level is reduced. Serine levels did not change
signiﬁcantly in hypoxia (Fig. 1k: p= 0.22 at 1% and p= 0.42 at
0.1%, unpaired t-test). In contrast, NAD+/NADH and conse-
quently SCI decreased with decreasing oxygen concentrations
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(Fig. 1l: p= 0.02 at 1% and p= 0.01 at 0.1%; Fig. 1m: p= 0.38 at
1% and p= 0.005 at 0.1%; unpaired t-test). This observation
conﬁrms the expectation that hypoxia shifts cells to a more
reduced state. In agreement with the SCI decrease, formate release
also decreased signiﬁcantly (Fig. 1n: p= 0.06 at 1% and p < 0.001
at 0.1%, unpaired t-test). Taken together the perturbation
analyses support our hypothesis that, regardless of the mechan-
ism, shifting cells towards a more oxidative state induces an
increase in formate release, while shifting cells towards a more
reductive state decreases formate release.
Previous work7, 10 indicates that competent mitochondrial one-
carbon metabolism is needed to observe formate overﬂow.
However, from that data we cannot exclude that defects in
mitochondrial one-carbon metabolism may push cells towards
a more reduced state, thereby inhibiting formate overﬂow. To
differentiate between these two factors we used CRISPR-Cas9
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engineered HAP1 cell lines that are either wild-type (WT), or
defective in cytosolic or mitochondrial one-carbon metabolism
by genetic knockout of SHMT1 or SHMT2, respectively8 (Fig. 1a,
Supplementary Fig. 28). The impairment of one-carbon metabo-
lism in ΔSHMT2 cells is reﬂected by a signiﬁcant decrease in their
proliferation rate relative to WT or ΔSHMT1 cells (Supplemen-
tary Fig. S2c). ΔSHMT2 cells exhibit higher serine levels (p= 0.04,
unpaired t-test), higher NAD+/NADH ratios (p= 0.01, unpaired
t-test) and consequently higher SCI (p= 0.02, unpaired t-test)
than WT or ΔSHMT1 cells (Fig. 1o–q). Furthermore, ΔSHMT2
cells have similar basal respiration rates than WT cells (Supple-
mentary Fig. 3). Therefore, the lack of formate release by
ΔSHMT2 cells (Fig. 1r) cannot be explained by a shift towards a
more reductive state nor by a decreased activity of oxidative
phosphorylation (Supplementary Fig. S3). In fact, despite a
similar oxygen consumption rate than WT cells, ΔSHMT2 cells
are in a more oxidative state (higher NAD+/NADH) and they
have higher serine levels than WT cells, which should promote
one-carbon production from the cytosolic pathway. Indeed, the
cytosolic pathway is able to compensate for the one-carbon
demand of biosynthesis, as demonstrated by the ~60% 13C-
enrichment in purine one-carbon units in all three HAP1
genotypes (P1C, Supplementary Fig. 4). However, the cytosolic
pathway seems to be incapable of reaching the high rates that are
needed for formate overﬂow (Fig. 1r, ΔSHMT2 cells).
Taken together with our previous data on serine require-
ment10, the chemical, environmental and genetic perturbations
indicate that serine availability, an oxidative cellular state and
competent mitochondrial one-carbon metabolism are necessary
conditions to manifest formate overﬂow.
13C–MeOH protocol to quantify serine catabolism in vivo. To
address the in vivo relevance of these in vitro observations, we
developed a 13C-methanol (13C–MeOH) tracing protocol to
quantify serine catabolism to formate in vivo (Fig. 2a). Methanol
is metabolized in the liver to formate in a two-step reaction:
conversion to formaldehyde by alcohol dehydrogenase and sub-
sequent conversion to formate by aldehyde dehydrogenase13.
Since the liver has a limited capacity for methanol turnover, we
hypothesized that an IP bolus of 13C-methanol may result in a
prolonged and steady infusion of 13C-formate into the blood
circulation. To test this hypothesis, an IP bolus of 13C-methanol
(3 g/kg) was injected in wild-type mice and blood and tissue
samples were collected at different time points. The 13C-
enrichment in plasma formate, plasma serine, liver serine and
spleen serine reached a steady value as soon as one-hour post-
injection and was maintained over 24 h (Fig. 2b–e). The 13C
enrichment of brain serine reached a steady state as well, but at a
later time between 3 to 24 h (Fig. 2f). The 13C-enrichment of
purines was detectable at the 20 h time point and reached a steady
level between 20 and 24 h (Fig. 2g–i). This slow kinetics was
expected given that the purine pool is higher and purine synthesis
rates are lower than the corresponding values for serine and
formate. Furthermore, different tissues have different rates
of purine synthesis that are manifested as different degrees of
13C-enrichment in purines (Fig. 2g–i). From the relative abun-
dance of purines with one (M+ 1) or two (M+ 2) 13C-atoms we
estimated the 13C-enrichment of intracellular formate, which
should be independent of the rate of purine synthesis. Indeed, the
deconvoluted 13C-enrichment of purines 1C units (P1C) is less
variable across tissues than the 13C-enrichment in purines
(Fig. 2j–l). These data indicate that IP injection of 13C–MeOH
can be used to reach isotopic steady state in relevant entities
(formate, serine, P1C).
Baseline rates of serine catabolism to formate in vivo. Using
the 13C–MeOH tracing protocol we developed an in vivo meta-
bolic ﬂux analysis to determine the relative rate of serine cata-
bolism to formate (SCF) (Fig. 3a). The methodology exploits
differences between the 13C-enrichment in tissue serine, plasma
formate and one-carbon units in purines (P1C) (Fig. 2). Serine
can be derived from the diet, produced from glucose catabolism
or synthesized from glycine and formate. Diet and glucose
derived serine dilute the 13C-enrichment of serine relative to
formate (Fig. 2c–f vs. Fig. 2b). Following the same rationale, the
one-carbon units in purines can be derived from serine catabo-
lism or from plasma formate (Fig. 3a). Since the 13C-enrichment
of tissue serine is always lower than the 13C-enrichment of
plasma formate (Fig. 2d–f vs. Fig. 2b), the observation that
the 13C-enrichment in P1C is lower than the 13C-enrichment of
plasma formate is evidence that there is catabolism of serine to
formate. The larger is the difference, the larger is the relative
contribution of serine catabolism to the one-carbon pool of the
tissue.
Applying this methodology, we estimated the baseline rate of
serine catabolism to formate in the context of normal physiology
and its relation with the tissue redox state. We proﬁled brain, liver
and spleen tissues that are characterized by distinctive metabolic
features. We focused on the two major factors affecting serine
catabolism in vitro, serine levels and the NAD+/NADH ratio.
Serine levels were the highest in the brain, intermediate in spleen,
and lowest in the liver (Fig. 3b). The NAD+/NADH ratio was the
highest in the spleen, intermediate in the brain and lowest in liver
(Fig. 3c). When combined together to calculate the SCI, brain
exhibits the highest SCI, spleen intermediate and liver the lowest
(Fig. 3d). This pattern is conﬁrmed by the relative rate of serine
catabolism to formate (SCF, Fig. 3e). SCF also exhibits its highest
value in the brain, intermediate in the spleen and lowest in the
liver tissue. Using the 13C–MeOH tracing protocol we have also
estimated the purine fraction that has been de novo synthesized
within the 24 h time window (Fig. 3f). The fraction of de novo
synthesized purines was higher in the liver (Fig. 3f), where the
estimated serine catabolism to formate is close to zero (SCF,
Fig. 3e). Furthermore, the fraction of de novo synthesized purines
was higher in the spleen than in the brain, the opposite of what
we determined for the relative rate of serine catabolism to formate
(SCF, Fig. 3e). Taken together these data indicate that in vivo
serine catabolism to formate is associated with serine levels and
the tissue redox state, but is not correlated with the rate of purine
synthesis.
Fig. 1 Formate overﬂow is controlled by the cell redox state in vitro. a Diagram of mammalian one-carbon metabolism with serine as the major substrate for
both anabolic and catabolic processes. b Correlation of formate release with the cell redox state estimated by the NAD+/NADH ratio. Symbols indicate
different cell lines (see legend and Supplementary Table 1). Black symbols indicate standard cell culture conditions, red symbols indicate treatment with the
complex I inhibitor rotenone (250 nM). The line represents a linear ﬁt excluding outlier (triangle down). c–f Metabolic proﬁle of HAP1 cells growing in
regular medium or medium with galactose (Gal) instead of glucose (Ctrl). g–jMetabolic proﬁle of HAP1 untreated cells (Ctrl) and cells treated with 50 nM
MTX. Signiﬁcant growth repression upon MTX is illustrated in Supplementary Fig. S1c. k–n Metabolic proﬁle of HAP1 cells under ambient oxygen (21%) or
moderate (1%) and deep (0.1%) hypoxia. o–r Metabolic proﬁle of HAP1 parental, ΔSHMT1 and ΔSHMT2 cells. For knockout validation and growth analysis
see Supplementary Fig. S2. Each dot indicates one independent experiment performed with triplicate wells. Each experiment was performed at least three
times. Error bars indicate s.e.m. p-values are calculated using an unpaired t-test with Welch’s correction. PCC Pearsson correlation coefﬁcient
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Increased serine catabolism to formate in APCMin/+ adenomas.
To determine whether serine catabolism to formate is increased
in cancer tissue we investigated the APCMin/+ model of intestinal
cancer. We analyzed tissue samples from brain, liver, spleen,
normal small intestine (N-SI) and adenoma bearing small intes-
tine (A-SI) of APCMin/+ mice with clinical manifestation of
the disease (Fig. 4a–d). Serine levels were found the highest
in adenomas of the small intestine, relative to adjacent non-
transformed small intestine tissue (p= 0.008, unpaired t-test)
and other normal tissues as well (Fig. 4a). In adenomas, the NAD
+/NADH ratio was lower than the highest values observed
in spleen (p= 0.03, unpaired t-test), but signiﬁcantly higher than
in the adjacent non-transformed small intestine tissue (p= 0.001,
unpaired t-test) (Fig. 4b). When combined together to calculate
the SCI, the adenomas exhibit the highest value, signiﬁcantly
higher than in the adjacent non-transformed small intestine tissue
(p= 0.004, unpaired t-test) (Fig. 4c). These ﬁndings indicate a
high tumor-speciﬁc potential for serine catabolism to formate.
We note that the increase of SCI in the intestinal adenomas is due
to both an increase in serine levels and the NAD+/NADH ratio.
Next, we deployed the 13C–MeOH tracing protocol to quantify
the rate of serine catabolism to formate and to test whether it is
indeed increased in the adenomas of APCMin/+ mice relative to
normal adjacent tissue. As observed in wild-type mice (Fig. 3), the
13C from MeOH was incorporated into formate, serine and
purines in all tissues proﬁled of APCMin/+ (Supplementary
Fig. 5a–d). From the measured 13C-enrichment in plasma
formate, tissue serine and the one-carbon of purines (Supple-
mentary Fig. 5a–d), we estimated the relative rate of serine
catabolism to formate (Fig. 4d). As reported above for wild-type
mice (Fig. 3e), the brain and spleen of APCMin/+ exhibit a
signiﬁcant rate of serine catabolism to formate. More importantly,
the rate of serine catabolism to formate in adenomas is
signiﬁcantly higher than in the small intestine tissue adjacent to
the adenomas (p < 0.001, unpaired t-test) and all the other tissues
analyzed (compared to brain: p= 0.02, compared to spleen: p=
0.01, unpaired t-test).
Increased serine catabolism to formate in PyMT tumors. As a
second independent model, we have investigated the PyMT
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model for mammary cancer. We analyzed tissue samples from
brain, liver, spleen, normal mammary gland (N-MG) and
mammary gland tumors (T-MG) of PyMT mice with clinical
manifestation of the disease (Fig. 4e–h). The data is strikingly
similar to that for the APCMin/+ model. Serine levels were found
the highest in the tumors, relative to adjacent non-transformed
mammary gland (p= 0.048, unpaired t-test) and other normal
tissues except brain (Fig. 4e). NADH levels where below detection
in some normal and in some tumor samples (Supplementary
Fig. S6). This indicates that mammary tissue is quite oxidative
and that this oxidative state is preserved in the tumor. To over-
come the caveat of dealing with zero or very low values of NADH,
we replaced the NAD+/NADH by the NAD+/(NADH+NAD+)
ratio. The latter is less sensitive to redox variations but it can cope
with scenarios where NADH is zero. The NAD+/(NADH+NAD
+) ratio in mammary tumors was comparable to the highest
values observed in spleen and normal mammary gland (Fig. 4f).
When combined together to calculate the SCI* (here deﬁned as
Serine x NAD+/(NADH+NAD+)), the brain tissue and the
mammary tumors exhibit the highest values (Fig. 4g). We note
that the increase of SCI in the mammary tumors compared to
adjacent non-transformed mammary gland tissue (p= 0.043,
unpaired t-test) is mainly due to an increase in serine.
Next, we deployed 13C–MeOH tracing to quantify the rate of
serine catabolism to formate in the different tissues in PyMT
mice. Here again the 13C from methanol was incorporated into
formate, serine and purines in all tissues proﬁled of PyMT
(Supplementary Fig. 5e–h), the data that is utilized to estimate the
relative rate of serine catabolism to formate (Fig. 4h). As reported
above for wild-type mice (Fig. 3e) and end-stage APCMin/+ mice
(Fig. 4d), the brain and spleen of end-stage PyMT mice exhibit a
signiﬁcant rate of serine catabolism to formate. More importantly,
the rate of serine catabolism to formate in the mammary tumors
is signiﬁcantly higher than in the mammary gland tissue adjacent
to the tumors (Fig. 4h, p= 0.002, unpaired t-test). The rate of
serine catabolism to formate in the mammary tumors is also
signiﬁcantly higher than in the brain (Fig. 4h, p= 0.02, unpaired
t-test), the tissue with highest value among all non-transformed
tissues analyzed.
Increased plasma formate levels in GEMMs. We have put
together all our estimates of serine catabolism to formate in wild-
type, APCMin/+ and PyMT mice (Fig. 4i). This aggregate data
shows that all normal tissues proﬁled, have no signiﬁcant changes
between wild-type and tumor bearing mice in the relative rate of
serine catabolism to formate. There is a trend towards increased
serine catabolism to formate in the spleen of APCMin/+ mice with
clinical manifestation of the disease (p= 0.08, unpaired t-test)
(Fig. 4i). However, there is a signiﬁcant and more dramatic
increase of the relative rate of serine catabolism to formate in the
adenoma/tumor tissues relative to adjacent normal tissue (Fig. 4i:
p < 0.001 for small intestine and p= 0.002 for mammary gland,
unpaired t-test). Overall, this data indicates a tumor-speciﬁc
increase in the relative rate of serine catabolism to formate.
To determine whether the tumor-speciﬁc increase in serine
catabolism to formate results in increased formate levels in
circulation, we have quantiﬁed plasma formate levels in wild-type
and tumor-bearing mice. First, we analyzed the serum of APCMin/
+ mice (80 days old pre-neoplastic and endpoint) and wild-type
controls. 80 days aged APCMin/+ mice show a signiﬁcant increase
in serum formate levels compared to controls (p= 0.005,
unpaired t-test) (Fig. 5a). Even though with less signiﬁcance,
increased formate levels were sustained until the mice reached
clinical endpoint (p= 0.09, unpaired t-test) (Fig. 5a). Since serine
catabolism to formate was increased in small intestinal adenomas
(Fig. 4d), this data indicates that the increased serum formate
levels reﬂect the increased serine catabolism in the adenomas.
Similar evidence was obtained when analyzing serum samples
from the PyMT model of mammary cancer. Tumor bearing
PyMT mice show a signiﬁcant increase in serum formate levels
compared to controls (p= 0.001, unpaired t-test) (Fig. 5b).
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Finally, we quantiﬁed formate levels in two other GEMMs for
cancer: lymphoma [Eμ-Myc] and pancreatic cancer [KPC]. We
found a signiﬁcant increase in serum formate in the serum of Eμ-
Myc endpoint mice (p= 0.034, unpaired t-test), but not in the
serum of KPC endpoint mice (p= 0.57, unpaired t-test) (Fig. 5c,d).
Therefore, our ﬁndings indicate that the increased rate of
serine catabolism to formate in adenomas/carcinomas can have a
signiﬁcant impact on peripheral levels of formate. It is interesting
to note that not all tumor-bearing mice have elevated formate
levels relative to wild-type controls. We have already identiﬁed
the KPC model as a counterexample.
Formate promotes cancer cell invasion in vitro. Increased for-
mate overﬂow could be a byproduct of increased serine catabo-
lism to sustain tumor growth. However, as reported above for
normal tissue physiology, there is no association between the
relative rate of serine catabolism to formate and purine synthesis
(Fig. 3e, f). An alternative hypothesis is that formate overﬂow
confers tumor cells with a selective advantage, independent of
growth. Since invasion is a hallmark of cancer associated with the
remodeling of the tumor microenvironment14, we investigated
whether formate levels modulate invasion. Towards this end, we
selected glioblastoma multiforme (GBM) as a tumor type repre-
sentative for a high degree of invasiveness. We used the GBM cell
lines U87 and LN229 out of our proﬁled cell line panel (Fig. 1b).
We also included NCH601 cells in our analyses, because of their
reported level of invasiveness15.
We performed invasion assays with these glioma cells using
Boyden chambers (Fig. 6a) to measure their invasion potential.
First, we titrated sodium formate in the cell culture medium of
wild type cells. Formate supplementation increased cell invasion
in a concentration dependent manner in all three cell lines tested
(Fig. 6b–d and Supplementary Fig. 9), indicating that formate
promotes glioma cell invasion. Next, we generated two indepen-
dent stable shRNA knockdown cell lines for MTHFD1L, the gene
encoding for the mitochondrial enzyme responsible for formate
production (Fig. 1a). The knockdown was carried out in LN229
cells and NCH601 cells (shMTHFD1L-1 and -2), along with non-
targeting shRNA controls (shCtrl). The knockdown was validated
by a decrease in protein expression and a reduction in formate
release (Supplementary Figs. 7 and 8). Except for one clone of
LN229 cells (LN229-shMTHFD1L-2), stable MTHFD1L knock-
down resulted in a signiﬁcant reduction of invasion relative to
shCtrl (Fig. 6e, f and Supplementary Figs. 10 and 11), providing
genetic evidence that endogenous serine one-carbon catabolism
with formate overﬂow promotes invasion. Finally, addition
of exogenous formate rescued the invasion reduction in the
shMTHFD1L knockdown cells (Fig. 6e, f and Supplementary
Figs. 10 and 11). To exclude growth effects that could impact
the number of invaded cells, we monitored growth of
shMTHFD1L cell lines versus shCtrl cells including different
formate concentrations. All cell lines grew at similar rates
independent of the genetic or chemical perturbation (Supple-
mentary Fig. 7). Furthermore, we validated that addition of
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sodium-formate to the growth medium did not alter the pH.
Taken together these data indicate that high levels of formate
generated by mitochondrial one-carbon metabolism or from
extracellular sources promote glioma cell invasion, either by an
intrinsic mechanism or by increasing extracellular formate
concentration.
Discussion
The in vitro evidence reported here, combined with previous
work5, 10, 11, demonstrates that serine availability, an oxidative
cellular state, and a competent mitochondrial one-carbon meta-
bolism are necessary conditions to manifest formate overﬂow.
The analysis of in vivo models of cancer indicates that both
increased serine levels and a highly oxidative state, can be man-
ifested in transformed tissues. These transformed tissues repre-
sent an environment promoting serine catabolism to formate.
Indeed, we determined that the relative rate of serine catabolism
to formate is increased in the analyzed transformed tissues rela-
tive to adjacent normal tissues and is the highest among all tissues
analyzed. This tumor-speciﬁc increase of serine catabolism to
formate is associated with increased levels of circulating formate.
Compared to normal controls, plasma levels of formate were
increased in GEMMs for intestinal adenoma, breast cancer and
lymphoma, but not for pancreatic cancer indicating that formate
overﬂow can be a frequent phenotype in tumors16.
Based on this evidence we propose an update of the key fea-
tures deﬁning cancer metabolism. There is a category of cancers
with putative poor oxidative metabolism, that are formate over-
ﬂow negative and most likely highly glycolytic (Fig. 7a). That is
cancer metabolism as envisioned by Warburg1. Yet, there is
another category of cancers with putative active oxidative meta-
bolism that are formate overﬂow positive (and potentially highly
glycolytic as well, Fig. 7b). The oxidative nature of such cancers is
so prominent that formate overﬂow translates to increased for-
mate concentrations in the circulation.
Our data also provide new evidence about a potential selective
advantage of increased mitochondrial one-carbon metabolism for
cancer development. It is well established that mitochondrial one-
carbon catabolism supplies the one-carbon units for cancer
growth6, 17, 18. Yet, in the absence of mitochondrial serine cata-
bolism, the cytosolic pathway can sustain cancer growth both
in vitro and in vivo7. Moreover, in the absence of both cytosolic
and mitochondrial serine catabolism, other sources of one
carbon units such as endogenous and exogenous formaldehyde
can sustain growth8. Based on the work presented here, we
identiﬁed an additional selective advantage, that high rates of
mitochondrial serine catabolism to formate, in excess of the
biosynthetic demand, promote invasion. We emphasize that
formate production needs to be in excess of biosynthetic demands
because knockdown of MTHFD1L does not inhibit proliferation
but, knockdown of MTHFD1L inhibits formate overﬂow and the
cell’s invasiveness, indicating that excess formate production is
required to promote the invasion phenotype. The mechanism of
how formate promotes invasion remains to be elucidated. Excess
formate production or formate supplementation may increase
intracellular formate levels and high intracellular formate could
be the signal promoting invasion. There is also the possibility of
non-cell autonomous effects, whereby formate overﬂow from a
group of cells could promote invasion by nearby cells. Additional
research is required to unravel the underlying mechanism on how
formate promotes invasion.
There have been previous reports indicating that knockdown of
MTHFD2, encoding for the enzyme catalyzing the second step of
mitochondrial one-carbon metabolism, reduces invasion19, 20.
However, this effect could have been mediated by one or more of
the different products of mitochondrial one-carbon metabolism
(Fig. 1a, formate, glycine, NAD(P)H and ATP). What is novel
about our observations is that the promotion of invasion is
mediated by formate. Addition of exogenous formate rescues the
inhibition of mitochondrial one-carbon metabolism. This link
between formate and invasion may also be relevant in the
context of embryonic development. Homozygous deletion of
genes encoding for mitochondrial serine catabolism enzymes is
embryonic lethal in mice21, 22 and the embryonic lethality can be
rescued by formate supplementation22. The parallel between
these observations in the context of embryonic development and
our observations in the context of cancer invasion assays suggest
a common explanation. It is worth mentioning that the major
phenotype associated with the embryonic lethality is neural tube
defects. Further research is required to determine whether a
reduction in formate overﬂow is the cause of the neural tube
defects.
Our ﬁndings open a whole array of new questions. Further
studies are needed to validate these results in a patient cohort,
study the implications of increased formate levels in the tumor
and blood and its potential as a biomarker for certain cancers. At
present, it is not clear which molecular, genetic or environmental
factors determine whether a tumor will exhibit formate overﬂow
and how the non-oxidative versus oxidative nature of cancers will
affect their response to cancer therapy. Finally, the mechanism of
how formate promotes invasion remains to be elucidated.
Methods
Chemicals. Methotrexate (sigma; M8407) was applied at a ﬁnal concentration of
50 nM for 16–20 h. Rotenone (sigma; R8875) was applied at a ﬁnal concentration
of 250 nM for 16–24 h. Galactose (sigma; G0750) was used instead of glucose at
17.5 mM in DMEM 5030 (thermo, A14430-01). Na-Formate was purchased from
Sigma (Nr. 71539).
O2
H2O
NADH
NAD+
ATP
ADP
Glucose
Lactate
ATP
ADP
Glucose
Lactate Formate
Serine
Formate overflow positiveFormate overflow negative
ba
Fig. 7 Two putative metabolic classes of cancers. a Cancers with low oxidative metabolism. These cancers are expected to be formate overﬂow negative.
b Cancers with active oxidative metabolism. These cancers are expected to be formate overﬂow positive
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Culturing and metabolic characterization of cell lines. All cell lines listed in
Supplementary Table 1 were obtained from American Type Culture Collection
(ATCC). Cells were regularly (once per month) tested for mycoplasma con-
tamination. No contaminations have been observed within the performed experi-
ments. Cells were cultured in DMEM 5030 supplemented with 17.5 mM glucose, 2
mM glutamine and 10% FBS at 5% CO2 and 37 C. HAP1 cells were obtained from
Patel’s laboratory8 and were cultured in IMDM medium supplemented with 10%
FBS. NCH601 cells (derived from the lab of Christel Herold-Mende, Heidelberg)
were cultured as non-adherent spheres in DMEM-F12 medium (Lonza) containing
1xBIT100 (Provitro), 2 mM glutamine, 30 U/ml Pen/Strep, 1 U/ml heparin
(Sigma), 20 ng/ml bFGF (Miltenyi) and 20 ng/ml EGF (Provitro) as previously
described in15, 23.
For metabolic proﬁling we deployed previously established protocols for
absolute quantiﬁcation of exchange ﬂuxes and intracellular ﬂuxes of one-carbon
metabolism10, 12, 24 to a panel of cancer cell lines. To determine the growth rate, we
assumed exponential growth and recorded start count and end count in every
experiment and calculated the growth rate as described in10. For the determination
of the SCI we calculated the product of serine level multiplied with the NAD
+/NADH ratio.
shRNA-mediated gene silencing. Gene knockdown with shRNA was performed
in LN229 and NCH601 cells using lentiviral particles expressing two different
shRNAs targeting the MTHFD1L gene and one non-targeting shRNA (shCtrl:
TTACTCTCGCCCAAGCGAG (Code: RHS4346); shMTHFD1L-1: ATGTGAGT-
GATGTTCAGAC (Code: V2LHS_96541); shMTHFD1L-2: TAGATTTCAATTT-
CATCTG (Code: V2LHS_96542)). Plasmids containing shRNA sequences were
ordered from Dharmacon. Lentiviral particles were produced in HEK293T cells by
co-transfection of the pGIPZ-shRNA-control or pGIPZ-shRNA-target gene vector
with the viral core packaging construct pCMVR8.74 and the VSV-G envelope
protein vector pMD2.G. Supernatant containing viral particles was used to trans-
duce 106 (LN229) or 4 × 105 cells (NCH601) and puromycin selection (1 μg/ml)
was applied to obtain stably transduced GFP-positive cells.
Western blot. Protein extracts were resolved in Novex 4–12% BisTris gels (Life
Technologies), and blotted onto a nitrocellulose membrane (Life Technology)
according to standard protocols and blocked with milk powder. Blots were incu-
bated at 4 °C overnight with primary antibodies speciﬁc for MTHFD1L (16113-1-
AP, Proteintech, diluted 1:1000), LaminB1 (ab16048, Abcam, diluted 1:1000),
SHMT1 (HPA023314, Sigma, diluted 1:250), SHMT2 (HPA020543, Sigma, diluted
1:250) or Vinculin (SAB4200080, Sigma, diluted 1:100000). Secondary antibodies
for the detection of primary antibodies against MTHFD1L and LaminB1 were
coupled to Horseradish peroxidase (HRP) (Goat anti rabbit HRP; 111-036-003;
Jackson ImmunoResearch, diluted 1:10000). To detect primary antibodies against
SHMT1, SHMT2 and Vinculin IRDye® 800CW Donkey anti-Rabbit IgG (H+ L)
(for SHMT1 and 2) or –anti mouse (for vinculin) was used (925–32213 (anti rabbit,
diluted 1:10,000), 925–32212 (anti mouse, diluted 1:10000), LiCor). Secondary
antibodies were incubated for 1 h at RT. In the case of HRP, signals were detected
with a chemiluminescent substrate (ThermoScientiﬁc) and imaged using the
ImageQuant 350 scanning system (GE Healthcare). In the case of IRDye, signals
were detected with a LiCor Odyssey image analyzer. For image analysis ImageS-
tudioLite Software was used.
Western Blots are presented in Supplementary Figs. 2 and 7. Uncropped scans
(including a molecular weight marker) are presented in Supplementary Figs. 2 and
8.
Invasion assays. The in vitro invasion potential was determined on collagen/
ECM-coated (0.05 mg/ml collagen type I (Sigma-Aldrich), 0.5 mg/ml protein of
ECM gel) transwell chambers with 8 μm pore size (Greiner Bio-one). For this, 300
μl cell suspension without FBS (with 5 × 104 cells) was added into the transwell in
duplicates per condition. 10% FBS was added to the medium in the bottom well
(750 µl total volume) as chemoattractant. In case of formate supplementation Na-
Formate (Sigma) was spiked from 100× stocks into the chambers. After 18 h
(LN229 and U87) or 72 h (NCH601), cells were ﬁxed with 4% PFA and stained
with 0.05% crystal violet solution for 15 min, respectively. Non-invading cells were
removed at the top of the chambers with Qtips and the invasion of GBM cells was
evaluated by counting the cells on the lower side of the membrane using a light
microscope at ×20 magniﬁcation (5 view ﬁelds/chamber).
Growth assay. For growth assay of LN229 and NCH601 cells the IncuCyte
instrument was used. For LN229 cells, 2.5 × 103 cells were seeded in 96-well plates
and imaged every 3 h using IncuCyte (Essen BioScience) (brightﬁeld, ×10 objective,
66 h). Conﬂuence was determined using the Incucyte analysis software. To evaluate
the NCH601 sphere growth over 93 h, 1 × 103 cells were plated in 384 wells. The
plate was shortly centrifuged before the experiment start to center the cells. Plates
were imaged and analyzed similar to LN229.
For growth analysis of HAP1 cells, 50,000 cells were plated in 12 well plates.
Growth was monitored over three days with one count per day.
Measurement of oxygen consumption rate (OCR). OCR was measured using the
Extracellular Flux analyzer (Seahorse Biosciences) as described in ref.10. For MTX
treatment: medium was replaced right before the assay with medium containing
50 nM MTX.
Animal models. All in vivo experiments were carried out in dedicated barriered
facilities proactive in environmental enrichment under the EU Directive 2010 and
Animal (Scientiﬁc Procedures) Act (HO licence numbers: 70/8645, 70/8468 and
70/8375) with ethical review approval (University of Glasgow). Animals were cared
for by trained and licensed individuals and humanely sacriﬁced using Schedule 1
methods.
Wild-type male C57BL/6J mice (stock number, 000664; at least 20 g in weight)
were purchased from Charles River.
APCMin/+ mice25 were bred in house on a C57BL/6J background (N6 or above).
Mice were monitored at least 2 times weekly and culled at 80 days or when
exhibiting symptoms of intestinal adenoma burden (weight loss, paling feet,
hunching). Tissues (serum, spleen, liver, and brain) were harvested and ﬂash frozen
on dry ice. The small intestine was ﬂushed with PBS; normal small intestinal tissue
and tumor tissues were dissected and snap frozen on dry ice.
Mouse Mammary Tumor Virus (MMTV) Polyoma Middle-T antigen (PyMT)26
(FVB/N >20 generations) female mice (hereafter PyMT mice) were killed
humanely when mammary tumors reached clinical endpoint as per regulation.
Litter-matched wild-type FVB females were used as controls.
Eu-MYC mice27 (>N20 C57BL/6J) were bred in house and monitored twice
weekly until manifestation of disease onset. Lymphomatous tissues (spleen/lymph
node) were harvested and ﬂash frozen on dry ice.
KPC (Pdx1-Cre; LSL-KrasG12D/+; LSL-Trp53R172H)28 mice were bred in house
on a mixed background. Mice were monitored at least 3 times weekly and culled
when exhibiting symptoms of pancreatic ductal adenocarcinoma (PDAC, swollen
abdomen, loss of body conditioning, jaundice, immobility or hunching), or before
the onset of symptoms or palpable tumor for pre-neoplastic lesion-enriched tissue.
Tissue was ﬂash frozen immediately upon harvest.
Tissue analysis. For each tissue one sample was generated per mouse, except for
small intestine and adenomas of small intestine. Here, 3–4 samples were analyzed
per mouse. Flash frozen tissue samples were blinded with random IDs and pro-
cessed by a different person for metabolite extraction and analysis. After ﬁnal data
analysis IDs were uncovered. Replicate values per mouse were pooled and the mean
value was used for further data analysis. All tissues were processed frozen on dry
ice. From each tissue 5–20 mg were balanced and transferred into Precellys CK14
tubes (Bertin Technologies, Montigny-le-Bretonnex, France). Tissues were dis-
solved in 20 mg/ml extraction solvent (Acetonitrile/MeOH/ H2O (30/50/20)) and
homogenized in a cooled Precellys 24 (Bertin Technologies, Montigny-le-Bre-
tonnex, France) with 3 × 20 s at 7200 r.p.m. and a 20 s break. Lysed tissue samples
were transferred into Eppendorf tubes and centrifuged for 10 min at 4 °C. Super-
natant was transferred into LC-MS vials for mass spec analysis.
13C-Methanol tracing. For 13C–MeOH tracing in wild type mice, mice were
randomized in individual groups (different time points and PBS controls). Mice
were sacriﬁced at respective time points. For 13C–MeOH tracing in APCMin/+ and
PyMT mice, mice were injected intraperitoneally with 3 g/kg 13C–MeOH (Eur-
isotop; CLM-359-1) when reaching clinical endpoint and sacriﬁced 24 h post
injection. Blood was immediately taken by cardiac puncture, transferred into
Eppendorf tubes and centrifuged at 4 °C for 10 min at 13k G. The supernatant was
transferred into new Eppendorf tubes and ﬂash frozen in liquid nitrogen. Tissues
were harvested in Eppendorf tubes, ﬂash frozen in liquid nitrogen and analyzed as
described above. All in vivo samples were blinded with random IDs and processed
by a different person for metabolite extraction and analysis. After ﬁnal data analysis
IDs were uncovered.
Metabolite extraction and analysis. Metabolite extraction and analysis was
performed as previously described10, 29. Brieﬂy, cells were washed with PBS once
and extracted with ice-cold extraction solvent (Acetonitrile/MeOH/ H2O (30/50/
20)), shaken for 5 min at 4 °C, transferred into eppendorf tubes and centrifuged for
5 min at 18k G. The supernatant was transferred in LC-MS glass vials and kept at
−80 °C until measurement. Formate extraction and derivatization was performed
as described in10 using a Methylchloroformate derivatization approach. Derivatized
formate was analyzed using GC-MS (Agilent). Heavy labeled M+ 2 formate was
used as internal standard for quantiﬁcation.
LC-MS analysis was performed as described previously10 using HILIC
chromatography and a Q-Exactive mass spectrometer (Thermo Fisher Scientiﬁc).
Raw data analysis was performed using TraceFinder (Thermo Fisher Scientiﬁc)
software. Peak areas were normalized to cell volume in case of in vitro experiments,
or to wet weight (mg) tissue.
13C enrichment in purine one carbon units (P1C). To calculate the 13C enrich-
ment in the two 1C units of purines (ATP, ADP, AMP, GTP, GDP, GMP) from
[13C]-formate, the purine mass isotopomer fractions were ﬁrst corrected by the
natural isotope abundance. The remaining M+ 1 and M+ 2 fractions are due to
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incorporation of 13C from formate at the two 1C units in purines. Assuming that
both carbons can be labeled with equal probability p, the purines M+ 1 and M+ 2
fractions are modeled by the equations P1= (1−P0)2p(1−p) and P2= (1−P0)p2,
respectively, where P0, P1, and P2 are the purines M+ 0,1,2 fractions, respectively.
Solving these equations for p we obtain P1C= p= 2P2/(P1+ 2P2). The reported
13C enrichment in the one-carbon units of purines was obtained using the latter
equation and the measured P1 and P2.
In vivo relative rate of serine catabolism to formate (SCF). To estimate the
relative rate of in vivo serine catabolism to formate we postulated a metabolic ﬂux
analysis (MFA) model whereby the formate incorporated into purines at a given
tissue comes from the serine one-carbon catabolism at that tissue or from plasma
formate. Within this model the tissue M+ 1 P1C (P1C1) is given by the equation
P1C1= sS1+ (1−s)F1, where s is the relative rate of serine one-carbon catabolism
(i.e., SCF), S1 is the fraction of tissue M+ 1 serine and F1 is the fraction of plasma
M+ 1 formate. Solving the latter equation for s we obtain s= (P1C1−F1)/(S1−F1).
In the liver we have the additional contribution of methanol conversion to formate,
resulting in P1C1= sS1+ (1−s–m)F1+m, where m is the relative rate of methanol
conversion to formate. Because this system has now two independent variables
(s and m) and only one equation, it is undetermined and we cannot determine s in
the liver. Our method works even when the in tissue conversion of 13C–MeOH to
formate is not taken into account. The reason why it works is that the method is
based on the difference between the 13C-enrichment in tissue serine, plasma for-
mate and one-carbon units in purines (P1C). Since 13C–MeOH is the source of
13C-formate, in situ conversion of 13C–MeOH to 13C-formate will tend to make
the 13C-P1C closer to the plasma 13C-formate. Therefore, the observation that 13C-
P1C is different from plasma 13C-formate, is evidence that there is catabolism of
serine to formate. The larger is the difference, the larger is the relative contribution
of the serine catabolism to formate. In a strict sense, the reported relative rate of
serine catabolism to formate is a lower bound to the actual value. That said, the
serine catabolism to formate could be even higher than what we report.
In vivo relative fraction of de novo synthesized purines. To estimate the
fraction of de novo synthesized purines (p) we took into account that the fraction
of M+ 0 purines is given by purines remaining from the pre-existing pool at the
start of the experiment (1−p) plus de novo synthesized purines with unlabeled one-
carbon units: P0= 1−p+ p[1−(1−P1C1)2]. Solving this equation for p we obtain
our working equation to estimate p given experimental measurements of P0 and
our previous estimate of P1C1: p= (1−P0)/(1−P1C1)2.
Statistics. Data was ﬁrst assessed to be eligible for respective statistical test. For
pairwise comparison an unpaired t-test with Welch’s correction was applied using
the GraphPad Software. The statistical signiﬁcance of PCC was estimated using a
permutation test with 1,000,000 permutations. For normalization of invasion data,
within one experiment, the mean value of the ten technical replicates (two
chambers with ﬁve images per chambers) per condition was calculated and divided
by the global mean of the experiment.
Data availability. The authors declare that all the data supporting the ﬁndings of
this study are available within the article and its Supplementary Information Files
and/or from the corresponding author upon reasonable request.
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